Drug News

Added 1 day ago Drug news

Data from ABSORB III study showed that Absorb Bioresorbable Vascular Stent was comparable in efficacy to the Xience metallic drug-eluting stent-Abbott

Abbott has announced that data from the ABSORB III U.S. pivotal trial showed that Absorb, Abbott's first-of-its-kind dissolving stent, had...

Added 1 day ago Drug news

Successful Phase III trial of Ameluz (5-aminolevulinic acid) with photodynamic therapy to treat actinic keratosis.- Biofrontera AG

Biofrontera AG announced detailed results from its Phase III clinical trial evaluating the safety and efficacy of its topical prescription...

Added 1 day ago Drug news

RLX 030 (serelaxin) fails to meet endpoints of reduction of cardiovascular death or worsening heart failure in RELAX-AHF-2.- Novartis

Novartis announced results from the global Phase III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of RLX 030 (serelaxin)...

Added 2 days ago Drug news

New data from Novartis suggests that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.

Novartis has announced new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis...

Added 3 days ago Drug news

Positive results from SUMMIT-07 Phase III efficacy study of NKTR-181, a first-in-class opioid analgesic.- Nektar Therapeutics

Nektar Therapeutics announced positive results from the SUMMIT-07 Phase III efficacy study of NKTR-181, a first-in-class opioid analgesic. The SUMMIT-07...

Added 3 days ago Drug news

Array BioPharma Inc.,withdraws from the FDA, binimetinib monotherapy for the treatment of NRAS-mutant melanoma.

Array BioPharma Inc. announced that it has withdrawn from the FDA Division of Oncology Products its new drug application (NDA)...

Added 3 days ago Drug news

Successful Phase III trial, MONARCH 2,of abemaciclib and fulvestrant for hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer.- Eli Lilly

Eli Lilly and Company announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS)....

Added 4 days ago Drug news

RE-CIRCUIT study of Pradaxa (dabigatran etexilate) shows less bleeding and fewer serious events in atrial fibrillation patients- Boehringer

New data from the RE-CIRCUIT study show a better safety profile for Pradaxa (dabigatran etexilate mesylate), from Boehringer, compared to...

Added 4 days ago Drug news

Study shows benefits of CardioMEMS HF System in heart failure- Abbott

New data supports the use of Abbott's CardioMEMS HF System as an effective real-world approach to reduce heart failure hospitalizations...

Added 5 days ago Drug news

Post-hoc analysis of PARADIGM-HF study shows Entresto (sacubitril/valsartan) improves glycemic control in patients with heart failure- Novartis

Novartis announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF)...

View all news articles